IntelliPharmaCeutics Announces Successful Completion of a Pilot Clinical Trial for its Abuse and Alcohol Resistant Sustained Release Oxycodone.
IntelliPharmaCeutics Ltd. today announced several parties have filed complaints alleging patent infringement in relation to it's FDA approved generic drug application.
IntelliPharmaCeutics Ltd. hasy announced that Par Pharmaceutical (NYSE: PRX) has made a significant equity investment in the Company.
